Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Other Routine +

Seegnal to Deploy its Medication Safety Platform Across Nazareth Hospital EMMS, Expanding its Israeli Hospital Footprint

Israeli med-tech SaaS expands domestic footprint while navigating severe liquidity constraints and unproven U.S. commercialization.

By The Northwire Desk — AI Analysis Jun 25, 2026 · 08:30 SEGN · 0.32 Seegnal Inc.
Executive Summary
  • Seegnal Inc. signed a five-year agreement to deploy its clinical decision support SaaS platform at Nazareth Hospital EMMS, a major regional trauma and teaching center in northern Israel.
  • The deployment will support approximately 424 medical staff members (188 physicians and 236 nurses) integrated into routine prescribing workflows.
  • The deal features recurring subscription fees over the initial term with an extension option.
  • The platform is now utilized by approximately 15,000 clinicians across Israeli healthcare settings.
  • The release highlights peer-reviewed clinical performance metrics, including 94% fewer inpatient alerts with 99% specificity and reductions in hospitalizations and medication dispensing.
Material Impact
  • The Nazareth Hospital agreement represents a standard, incremental commercial expansion within Seegnal's established Israeli market. It adds predictable recurring revenue but is immaterial to the company's overall financial profile given its micro-cap status and current cash burn.
  • The deal does not alter the company's fundamental risk profile. It does not address the material going-concern uncertainty, negative working capital, or the need for larger-scale capital raises to fund U.S. expansion and R&D.
  • The clinical metrics cited are consistent with prior management commentary and do not represent new, unexpected data that would re-rate the business model.
SEGN · Price
Company Overview
  • Seegnal Inc. is an Israeli-based med-tech SaaS company developing a clinical decision support system focused on medication safety and prescription intelligence.
  • The platform integrates patient-specific data (medications, lab results, renal function, allergies, age) to deliver context-aware alerts, aiming to reduce alert fatigue, adverse drug events, and hospitalizations.
  • The technology is currently deployed across Israeli healthcare settings, utilized by over 15,000 clinicians, and processes more than 400,000 prescriptions daily.
  • Management is actively pursuing commercial expansion into the United States, targeting long-term care and nursing facilities, while maintaining its core Israeli operations.
Read the original news release →

More from Seegnal Inc.

Jun 19, 2026 · 08:30

Seegnal Successfully Initiates First U.S. Pilot Program

Production / Operations Jun 05, 2026 · 08:30

Seegnal Inc. - AI-Driven Prescription Intelligence Platform for Medication Safety

M&A / Property Jun 02, 2026 · 17:00

Seegnal Raises $1.3M at a Discount to Fund Burn Rate as Filing Delays and Going Concern Risks Mount

Financings May 19, 2026 · 08:30

Seegnal Eyes U.S. Expansion Amid Regulatory Filing Overhang

Other May 06, 2026 · 17:00

Filing Default Lingers as Seegnal Pushes Audit Deadline

Regulatory Apr 30, 2026 · 23:41

Seegnal to miss April 30 financial filing deadline

Regulatory